Deceased donor neutrophil gelatinase-associated lipocalin and delayed graft function after kidney transplantation: a prospective study

Table 3 Donor NGAL, donor kidney function and onset of graft function after transplantation^a

Parameter	High S-NGAL (≥214 ng/mL)	Low S-NGAL (< 214 ng/mL)	P value	High U-NGAL (≥18 ng/mL)	Low U-NGAL (≥18 ng/mL)	P value
Donors, n	38	57		26	69
Kidneys, n	69	99		52	116
Mean donor plasma creatinine, μmol/L (± SD)	70 (22.8)	57 (± 15.1)	0.021	71 (± 21.8)	59 (± 17.8)	0.006
Mean donor eGFR, mL/min (± SD)	108 (33.9)	124 (± 34.5)	0.033	105 (± 31.2)	122 (± 35.7)	0.039
Prolonged DGF (n = 25)	12 (17.4%)	13 (13.1%)		12 (23.1%)	13 (11.2%)
Short DGF (n = 41)	22 (31.9%)	19 (19.1%)		15 (28.8%)	26 (22.4%)
EGF (n = 102)	35 (50.7%)	67 (67.8%)	NS	25 (48.1%)	77 (66.4%)	0.028
Mean recipient 1-year plasma creatinine level, μmol/L (± SD)	117 (43.8)	115 (± 37.7)	NS	114 (± 28.5)	117 (± 45.0)	NS
Mean Recipient 1-year eGFR mL/min (± SD)	57 (16.9)	60 (± 21.1)	NS	57 (± 15.9)	59 (± 21.4)	NS
1-year patient survival	98.6%	99.0%	NS	96%	100%	NS
1-year graft survival	91.4%	98.0%	0.050	90.3%	97.4%	0.048

^aDGF, delayed graft function; EGF, early graft function; S-NGAL, serum neutrophil gelatinase-associated lipocalin; U-NGAL, urine neutrophil gelatinase-associated lipocalin.

ISSN: 1364-8535